CABA Stock Chart & Stats
$50.00
$0.00(0.00%)
At close: 4:00 PM EDT
$50.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$26.08 - $67.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$5.07B
Enterprise Value$270.72M
Total Cash (Recent Filing)$225.10M
Total Debt (Recent Filing)$25.71M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Nov 05, 2026EPS Estimate
-5.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding169,545,440
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$272.13Price Target Upside444.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-25.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Autoimmune Cell-therapy PipelineA focused pipeline aimed at B cell-mediated autoimmune diseases gives Cabaletta a defined strategic direction and exposure to significant unmet medical needs. Concentrating resources on related indications may support platform development and clinical learning across programs over the next several quarters.
Low Financial LeverageLow leverage and a materially stronger equity base improve financial flexibility relative to a more debt-dependent capital structure. This reduces immediate balance-sheet pressure and gives the company greater capacity to continue funding research and operations while clinical programs progress.
Substantial Capital InfusionThe sizable warrant-related capital infusion strengthens near-term liquidity and can fund development programs and operating needs without relying solely on additional immediate financing. Greater cash resources provide more runway for clinical execution and may support continuity across the pipeline.
Bears Say
Pre-revenue Business ModelWithout approved products or recurring sales, Cabaletta has no commercial revenue base to offset research and development spending. Its financial outlook therefore remains dependent on clinical progress, collaboration-related receipts, or additional financing until a program reaches commercialization.
Widening Net LossesThe multi-year expansion in net losses shows that operating costs remain high while commercial revenue is absent. Persistently worsening profitability can reduce financial resilience, increase the amount of capital required to reach milestones, and make future results highly dependent on successful development outcomes.
Heavy And Worsening Cash BurnCash burn has increased substantially over time and closely tracks net loss, indicating that reported losses are translating into significant cash outflows. Continued negative cash generation creates an ongoing need for external funding and could constrain development if financing conditions or investor support weaken.
Cabaletta Bio News
CABA FAQ
What was Cabaletta Bio’s price range in the past 12 months?
Cabaletta Bio lowest stock price was $26.08 and its highest was $67.00 in the past 12 months.
What is Cabaletta Bio’s market cap?
Cabaletta Bio’s market cap is $5.07B.
When is Cabaletta Bio’s upcoming earnings report date?
Cabaletta Bio’s upcoming earnings report date is Nov 05, 2026 which is in 5 days.
How were Cabaletta Bio’s earnings last quarter?
Cabaletta Bio released its earnings results on Aug 13, 2026. The company reported -$6.387 earnings per share for the quarter, beating the consensus estimate of -$7.007 by $0.62.
Is Cabaletta Bio overvalued?
According to Wall Street analysts Cabaletta Bio’s price is currently Undervalued.
Does Cabaletta Bio pay dividends?
Cabaletta Bio does not currently pay dividends.
What is Cabaletta Bio’s EPS estimate?
Cabaletta Bio’s EPS estimate is -5.96.
How many shares outstanding does Cabaletta Bio have?
Cabaletta Bio has 169,545,440 shares outstanding.
What happened to Cabaletta Bio’s price movement after its last earnings report?
Cabaletta Bio reported an EPS of -$6.387 in its last earnings report, beating expectations of -$7.007. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cabaletta Bio?
Currently, no hedge funds are holding shares in MX:CABA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cabaletta Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$272.13 (444.27% Upside)
$272.13 (444.27% Upside)
Blogger Sentiment
Bullish
MX:CABA Sentiment 100%
Sector Average 64%
Sector Average 64%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.60%
12-Months-Change
Fundamentals
Return on Equity
-128.27%
Trailing 12-Months
Asset Growth
14.36%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cabaletta Bio
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
CABA Stock 12 Month Forecast
Average Price Target
$272.13
▲(444.27% Upside)